ALEC - Alector, Inc.
21.38 0.00 (0.00%)
After hours: 4:30PM EST
| Previous Close | 19.89 |
| Open | 20.06 |
| Bid | 17.35 x 1400 |
| Ask | 21.37 x 800 |
| Day's Range | 19.86 - 21.80 |
| 52 Week Range | 13.64 - 27.00 |
| Volume | 566,139 |
| Avg. Volume | 353,590 |
| Market Cap | 1.474B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
- GlobeNewswire
Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon.
- GlobeNewswire
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
AL101 is the company’s second product candidate designed to increase the level of progranulin in the human brain. Progranulin has been identified as a key regulator of microglial function in the brain with strong genetic links to multiple neurodegenerative disorders. SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December 2019, it initiated dosing in healthy volunteers in its Phase 1 study of AL101, an investigational product candidate designed to increase progranulin levels.
- GuruFocus.com
Insiders Roundup: Nike, Eastman Kodak
Largest insider trades of the week Continue reading...
- GlobeNewswire
Alector Added to the NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been.
- GlobeNewswire
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC). As co-chairs of SPARC, Drs. Scheller and Südhof will serve as key R&D leaders supporting the advancement of Alector’s research pipeline and proprietary drug discovery platform.
- GlobeNewswire
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will provide updates related to its lead product candidates during a previously announced R&D day being held today at 8:00 a.m. ET in New York, NY. During today’s session, Alector will outline key activities underway for AL001, AL002, AL003, AL101, and AL014, and will feature presentations from leading key opinion leaders focused on the human genetics of neurodegeneration.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Alector, Inc. (ALEC)
Is Alector, Inc. (NASDAQ:ALEC) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
- GlobeNewswire
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as the company’s president and chief operating officer. In this new role, Dr. Suliman will oversee Alector’s day-to-day operations, including preclinical development, program management, and strategic and administrative functions. Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.
- GlobeNewswire
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) meeting being held December 4-6 in San Diego, California.
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- GlobeNewswire
Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic, AL001, for the treatment of patients with frontotemporal dementia (FTD) carrying specific genetic mutations in the granulin gene (FTD-GRN). AL001 is the company’s product candidate currently being evaluated in a Phase 2 trial for the treatment of FTD-GRN and FTD-C9orf72.
- GlobeNewswire
Alector to Host R&D Day on December 13, 2019
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will.
- GlobeNewswire
Alector to Present at the Jefferies 2019 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney,.
- GlobeNewswire
Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results
Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a C9orf72 mutation (FTD-C9orf72)Initiated.
- Zacks
4 Biotech Stocks That Could Keep Beating Wall Street
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Alector, Inc. (ALEC)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- Zacks
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
- Zacks
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
- Simply Wall St.
Alector, Inc.'s (NASDAQ:ALEC) Single Biggest Risk For Investors
As the US$1.3b market cap Alector, Inc. (NASDAQ:ALEC) released another year of negative earnings, investors may be on...
- GlobeNewswire
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the treatment of people with frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN). “We are encouraged by the recent data from our Phase 1b trial of AL001, in which AL001 was well-tolerated and restored progranulin back to normal physiological levels in the central nervous system of FTD-GRN patients,” said Robert Paul, M.D, Ph.D., chief medical officer of Alector.
- GlobeNewswire
Alector to Present at 17th Annual Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Arnon.
- GlobeNewswire
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results
- Completed planned enrollment of AL001 Phase 1b trial and demonstrated proof-of-mechanism in Frontotemporal Dementia patients - AL101 granted Orphan Drug Designation from.
- GlobeNewswire
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
Alector, Inc. (ALEC) today announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors. Dr. Yaffe is the Scola Endowed Chair and Vice Chair, professor of psychiatry, neurology and epidemiology and the director of the Center for Population Brain Health at the University of California, San Francisco (UCSF). “Kristine is an internationally recognized expert in the field of cognitive aging, neurodegeneration and dementia,” said Arnon Rosenthal, Ph.D., chief executive officer of Alector.
- Zacks
AC Immune Initiates Phase I Study for Alzheimer's Disease
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
- GlobeNewswire
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).
